Transasia’s ELISA test kits approved by the Indian Council of Medical Research (IMCR)

Transasia’s ErbaLisa COVID-19 IgG test kits, approved by ICMR, to play a crucial role in mass screening and easing of the lockdown.

Image Credit: https://unsplash.com

Transasia Bio-Medicals Ltd. announced wide availability of its recently launched ELISA antibody test kits through its countrywide network of over 50,000 diagnostic labs. Named the ErbaLisa COVID-19 IgG, the ELISA test kits are 98% accurate and come at 20% the cost of RT-PCR tests.

Mr Suresh Vazirani, Chairman and Managing Director, Transasia-Erba Group said: “With the country slowly trying to emerge from the lockdown and resume functionality, there is a need to scale up testing by at least five times in the next three months. ICMR’s mantra of Test, Track and Treat is very relevant in India to flatten the curve. ELISA test is a promising tool for sero surveillance and to know where the disease stands in the curve. It is with this thought that Antibody ELISA tests are being widely conducted in the US and Europe.”

Mr Ravi Kaushik, CEO, Transasia Bio-Medicals Ltd. said: “Most labs in India are already equipped with ELISA automation and technicians are well trained for conducting ELISA tests, thus making it the ‘most conducive environment’ for testing. Compared to RT-PCR, the gold standard of testing, ELISA costs 80% lesser and allows for volume testing in a short time. The approved Rapid Ag tests, on the other hand, have a sensitivity of 50%, making it less reliable and requiring re-testing of large populations.”

Mr Vazirani added: “All through the lockdown, our manufacturing facilities continued to work to meet the demands of the Indian and global healthcare customers. Our sales and service frontline warriors attended to close to 30,000 Doctors and lab technicians, to ensure uninterrupted services. With all these initiatives, Transasia remains committed to a Healthy and Atmanirbhar Bharat.”